ERBB2 and breast cancer: Although HER2 amplification was thought to indicate a tumor subtype that would benefit from the addition of an anthracycline in an era that predated trastuzumab, no randomized study has shown the addition of anthracycline to a taxane/trastuzumab-based regimen improves outcomes for HER2-amplified breast cancer.